<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34840031</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study.</ArticleTitle><Pagination><StartPage>112243</StartPage><MedlinePgn>112243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2021.112243</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(21)01027-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr): Gr. 1 control (n&#xa0;=&#xa0;8) - Standard treatment; Gr. 2: Standard treatment +&#xa0;AFO-202 beta glucan (n&#xa0;=&#xa0;8); and Gr. 3, Standard treatment +&#xa0;combination of AFO-202 and N-163 beta glucans (n&#xa0;=&#xa0;8) for 30 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751&#xa0;ng/ml to 143.89&#xa0;ng/ml) and IL-6 values (7.395-3.16&#xa0;pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer: 202.5&#xa0;ng/ml; IL-6 55.37&#xa0;pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer: 560.99&#xa0;ng/dl to 79.615; IL-6: 26.18-3.41&#xa0;pg/ml) and 3 (D-dimer: 1614&#xa0;ng/dl to 164.25&#xa0;ng/dl; IL-6: 6.25-0.5&#xa0;pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4&#xa0;+&#xa0;and CD8&#xa0;+&#xa0;T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>Kadalraja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dept of Paediatric Neurology, Kenmax Healthcare Services Pvt Ltd, Madurai, India; Research &amp; Development Division, Sarvee Integra Pvt Ltd, Chennai, India; Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: drkraghavan@nichimail.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedeepiya</LastName><ForeName>Vidyasagar Devaprasad</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: dedeepiya_76@yahoo.co.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suryaprakash</LastName><ForeName>Vaddi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Urology, Yashoda Hospitals, Hyderabad, India. Electronic address: suryaprakashuro@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Kosagi-Sharaf</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Cient&#xed;ficas y Servicios de Alta Tecnolog&#xed;a (INDICASAT AIP), City of Knowledge, Panama. Electronic address: jrao@indicasat.org.pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikewaki</LastName><ForeName>Nobunao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan; Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan. Electronic address: nikewaki@phoenix.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonoda</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan. Electronic address: sonodat@phoenix.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Gary A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Professor Emeritus, Medicine and Immunology, University of Toronto, Ontario, Canada. Electronic address: gary.levy@uhn.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan. Electronic address: miwasaki@yamanashi.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senthilkumar</LastName><ForeName>Rajappa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: rsk@nichimail.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preethy</LastName><ForeName>Senthilkumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: drspp@nichimail.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Samuel Jk</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India; Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan; Antony, Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu, Japan. Electronic address: drsam@nichimail.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047071">beta-Glucans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000662986">Aureobasidium pullulans</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000084644" MajorTopicYN="Y">Aureobasidium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="Y">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047071" MajorTopicYN="N">beta-Glucans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjunct treatment</Keyword><Keyword MajorTopicYN="N">Beta glucans</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coagulopathy</Keyword><Keyword MajorTopicYN="N">Cytokine storm</Keyword><Keyword MajorTopicYN="N">D-dimer</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">Immuno-modulation</Keyword></KeywordList><CoiStatement>Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>29</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34840031</ArticleId><ArticleId IdType="pmc">PMC8463314</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2021.112243</ArticleId><ArticleId IdType="pii">S0753-3322(21)01027-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bioithas SL (2021) The intestinal microbiota as a therapeutic target in hospitalized patients with COVID-19 infection. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04390477.</Citation></Reference><Reference><Citation>Ciecierska A., Drywie&#x144; M.E., Hamulka J., Sadkowski T. Nutraceutical functions of beta-glucans in human nutrition. Rocz. Panstw. Zakl. Hig. 2019;70(4):315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">31960663</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes E.A., Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev. Med. Virol. 2020;30(6):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy G.A., Talbot P.J., editors. Advances in Experimental Medicine and Biology. Springer; US: 1995. Corona- and related viruses. current concepts in molecular biology and pathogenesis.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1899-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid-19: Has India's deadly second wave peaked? (August 6, 2021). https://www.bbc.com/news/world-asia-india-57225922.</Citation></Reference><Reference><Citation>Dhar D., Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020;285</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217790</ArticleId><ArticleId IdType="pubmed">32430279</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghahramani S., Tabrizi R., Lankarani K.B., Kashani S., Rezaei S., Zeidi N., Akbari M., Heydari S.T., Akbari H., Nowrouzi-Sohrabi P., Ahmadizar F. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur. J. Med. Res. 2020;25(1):30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396942</ArticleId><ArticleId IdType="pubmed">32746929</ArticleId></ArticleIdList></Reference><Reference><Citation>How Delta variant is causing new spikes across the world? (August 6, 2021). https://timesofindia.indiatimes.com/india/how-delta-variant-is-causing-new-spikes-across-the-world/articleshow/84824814.cms.</Citation></Reference><Reference><Citation>How Dangerous Is the Delta Variant (B.1.617.2)? (August 6, 2021). https://asm.org/Articles/2021/July/How-Dangerous-is-the-Delta-Variant-B-1&#x2013;617-2.</Citation></Reference><Reference><Citation>ICMR COVID-19 Management protocol. (August 6, 2021). https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Management_Algorithm_17052021.pdf.</Citation></Reference><Reference><Citation>Ikewaki N., Fujii N., Onaka T., Ikewaki S., Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a health food supplement. Microbiol. Immunol. 2007;51(9):861&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895603</ArticleId></ArticleIdList></Reference><Reference><Citation>aIkewaki N., Iwasaki M., Abraham S. Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients. J. Diabetes Metab. Disord. 2020;19(2):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575334</ArticleId><ArticleId IdType="pubmed">33102263</ArticleId></ArticleIdList></Reference><Reference><Citation>bIkewaki N., Rao K.S., Archibold A.D., Iwasaki M., Senthilkumar R., Preethy S., Katoh S., Abraham S. Coagulopathy associated with COVID-19 &#x2013; perspectives &amp; Preventive strategies using a biological response modifier Glucan!Abstract. Thromb. J. 2020;18:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7563912</ArticleId><ArticleId IdType="pubmed">33082714</ArticleId></ArticleIdList></Reference><Reference><Citation>aIkewaki N., Iwasaki M., Kurosawa G., Rao K.S., Lakey-Beitia J., Preethy S., Abraham S.J. beta glucans: wide-spectrum immune-balancing food-supplement-based enteric (&#x3b2;-WIFE) vaccine adjuvant approach to COVID-19. Hum. Vaccin. Immunother. 2021:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938654</ArticleId><ArticleId IdType="pubmed">33651967</ArticleId></ArticleIdList></Reference><Reference><Citation>bIkewaki, N. , Raghavan, K. , Dedeepiya, V.D. , Suryaprakash, V. , Iwasaki, M. , Preethy, S. , Senthilkumar, R. , Abraham, S. (2021). Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats. 02 August 2021, PREPRINT (Version 1) Research Square; doi:10.21203/rs.3.rs-771315/v1.</Citation></Reference><Reference><Citation>cIkewaki N., Kurosawa G., Iwasaki M., Preethy S., Dedeepiya V.D., Vaddi S., Senthilkumar R., Levy G.A., Abraham S. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. bioRxiv. 2021 doi: 10.1101/2021.07.08.451700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.08.451700</ArticleId><ArticleId IdType="pmc">PMC9630018</ArticleId><ArticleId IdType="pubmed">36340302</ArticleId></ArticleIdList></Reference><Reference><Citation>dIkewaki N., Sonoda T., Kurosawa G., Iwasaki M., Dedeepiya V.D., Senthilkumar R., Preethy S., Abraham S. Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: an exploratory study. medRxiv. 2021 doi: 10.1101/2021.08.05.21261640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.05.21261640</ArticleId><ArticleId IdType="pmc">PMC10457473</ArticleId><ArticleId IdType="pubmed">37637272</ArticleId></ArticleIdList></Reference><Reference><Citation>eIkewaki N., Dedeepiya V.D., Iwasaki M., Abraham S. Commentary: beyond &#x201c;TRIM&#x201d; benefits of &#x3b2;-glucan by blood glucose and lipid balancing potentials in its defense against COVID-19. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8039283</ArticleId><ArticleId IdType="pubmed">33854499</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaf D.E., Ginde A.A. Vitamin D3 to Treat COVID-19: different disease, same answer. JAMA. 2021;325(11):1047&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412177</ArticleId><ArticleId IdType="pubmed">33595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mej&#xed;a F., Medina C., Cornejo E., Morello E., V&#xe1;squez S., Alave J., Schwalb A., M&#xe1;laga G. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. PLoS One. 2020;15(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769479</ArticleId><ArticleId IdType="pubmed">33370364</ArticleId></ArticleIdList></Reference><Reference><Citation>Musoke N., Lo K.B., Albano J., Peterson E., Bhargav R., Gul F., DeJoy R., 3rd, Salacup G., Pelayo J., Tipparaju P., Azmaiparashvili Z., Patarroyo-Aponte G., Rangaswami J. Anticoagulation and bleeding risk in patients with COVID-19. Thromb. Res. 2020;196:227&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7444469</ArticleId><ArticleId IdType="pubmed">32916565</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu S.L., Zhang X.Y., Liu D.S., Ye B.N., Li J.Q. Unexplained elevation of erythrocyte sedimentation rate in a patient recovering from COVID-19: A case report. World J. Clin. Cases. 2021;9(6):1394&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896696</ArticleId><ArticleId IdType="pubmed">33644207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao K.S., Suryaprakash V., Senthilkumar R., Preethy S., Katoh S., Ikewaki N., Abraham S. Role of immune dysregulation in increased mortality among a specific subset of COVID-19 patients and immune-enhancement strategies for combatting through nutritional supplements. Front. Immunol. 2020;11:1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363949</ArticleId><ArticleId IdType="pubmed">32733487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabico S., Enani M.A., Sheshah E., Aljohani N.J., Aldisi D.A., Alotaibi N.H., Alshingetti N., Alomar S.Y., Alnaami A.M., Amer O.E., Hussain S.D., Al-Daghri N.M. Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate COVID-19: a randomized clinical trial. Nutrients. 2021 24;13(7):2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8308273</ArticleId><ArticleId IdType="pubmed">34202578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabaka P., Ko&#x161;&#x10d;&#xe1;lov&#xe1; A., Straka I., Hodosy J., Lipt&#xe1;k R., Kmotorkov&#xe1; B., Kachl&#xed;kov&#xe1; M., Ku&#x161;n&#xed;rov&#xe1; A. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect. Dis. 2021;21(1):308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006112</ArticleId><ArticleId IdType="pubmed">33781216</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberstein M. Vitamin D: a simpler alternative to tocilizumab for trial in COVID-19? Med. Hypotheses. 2020;140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177149</ArticleId><ArticleId IdType="pubmed">32353742</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni M., Gopalakrishnan R., Vaishya R., Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases. Diabetes Metab. Syndr. 2020;14(6):2245&#x2013;2249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670909</ArticleId><ArticleId IdType="pubmed">33395786</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Solidarity&#x201d; clinical trial for COVID-19 treatments (August 6, 2021). Retrieved from &#x3008;https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-COVID-19-treatments&#x3009;.</Citation></Reference><Reference><Citation>Stroehlein J.K., Wallqvist J., Iannizzi C., Mikolajewska A., Metzendorf M.I., Benstoem C., Meybohm P., Becker M., Skoetz N., Stegemann M., Piechotta V. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst. Rev. 2021;5(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406457</ArticleId><ArticleId IdType="pubmed">34029377</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S., Patel D., Bittel B., Wolski K., Wang Q., Kumar A., Il&#x2019;Giovine Z.J., Mehra R., McWilliams C., Nissen S.E., Desai M.Y. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients With SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw. Open. 2021;4(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881357</ArticleId><ArticleId IdType="pubmed">33576820</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard (August 6, 2021). https://covid19.who.int/.</Citation></Reference><Reference><Citation>Winthrop K.L., Mariette X. To immunosuppress: whom, when and how? That is the question with COVID-19. Ann. Rheum. Dis. 2020;79(9):1129&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456547</ArticleId><ArticleId IdType="pubmed">32753413</ArticleId></ArticleIdList></Reference><Reference><Citation>Weill P., Plissonneau C., Legrand P., Rioux V., Thibault R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? Biochimie. 2020;179:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481803</ArticleId><ArticleId IdType="pubmed">32920170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X.S., Jiang D., Gao L., Zhou J.Z., Xiao J., Cheng X.C., He B., Chen Y., Lei P., Tan X.W., Qin S., Zhang D.Y. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect. Dis. 2021;21(1):57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803000</ArticleId><ArticleId IdType="pubmed">33435865</ArticleId></ArticleIdList></Reference><Reference><Citation>Varchetta S., Mele D., Oliviero B., Mantovani S., Ludovisi S., Cerino A., Bruno R., Castelli A., Mosconi M., Vecchia M., Roda S., Sachs M., Klersy C., Mondelli M.U. Unique immunological profile in patients with COVID-19. Cell. Mol. Immunol. 2021;18(3):604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557230</ArticleId><ArticleId IdType="pubmed">33060840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H.H., Qin C., Chen M., Wang W., Tian D.S. D-dimer level is associated with the severity of COVID-19. Thromb. Res. 2020;195:219&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384402</ArticleId><ArticleId IdType="pubmed">32777639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Kang Z., Gong H., Xu D., Wang J., Li Z., Cui X., Xiao J., Meng T., Zhou W., Liu J., Xu H. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020 doi: 10.1101/2020.01.30.927806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.01.30.927806</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>